Expand CVM Menu
CVM MENU

CVM Latest Press Releases

-- August 4, 2026 --

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study Business Wire 8:00 AM

-- July 30, 2026 --

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients Business Wire 8:31 AM

-- July 13, 2026 --

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine to Market for Newly Diagnosed Head and Neck Cancer Business Wire 8:00 AM

-- June 24, 2026 --

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.-Saudi Cooperation in Cancer Care Business Wire 8:00 AM

-- June 16, 2026 --

CEL-SCI Announces Closing of Offering Business Wire 4:01 PM
CEL-SCI Advances Multikine Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy Business Wire 8:00 AM

-- June 14, 2026 --

CEL-SCI Corporation Announces Pricing of Offering Business Wire 7:03 PM

-- June 12, 2026 --

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine in Saudi Arabia Business Wire 8:00 AM

-- May 18, 2026 --

CEL-SCI Reports Fiscal Second Quarter 2026 Results Business Wire 8:00 AM

-- May 13, 2026 --

CEL-SCI Announces Closing of Public Offering Business Wire 3:00 PM

-- May 11, 2026 --

CEL-SCI Corporation Announces Pricing of Public Offering Business Wire 8:11 PM
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia Business Wire 8:00 AM
Market Data Delayed 15 Minutes